Publicaciones científicas
Engineering Anti-myeloma Responses Using Affinity-Enhanced TCR-Engineered T Cells
14-sep-2015
| Revista: Cancer Cell
San Miguel JF (1), Paiva B (2), Lasarte JJ (2).
RESUMEN
NY-ESO-1 TCR-engineered T cells have shown activity in solid tumors.
Recent work supports their use in multiple myeloma by showing that ex vivo antigen-specific expanded T cells traffic to and persist in bone marrow, are well tolerated, and produce promising response rates when infused after stem cell transplantation.
CITA DEL ARTÍCULO Cancer Cell. 2015 Sep 14;28(3):281-3. doi: 10.1016/j.ccell.2015.08.009.